BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Vote in favor of Your #1 4\u00d74 SUVs- Remote Headphones: Upgrade Your Sound Insight
- Vial marked 'Polonium 210' sparks scare during German Easter egg hunt
- Overlooked infertility care should be part of national health services, says WHO
- Israel says Iran's military industry will be destroyed 'within days'
- Collins Foods to offload 20 Taco Bell outlets in Australia
- Airbnb Unveils Airport Pickup Service Across 125 Cities in Global Expansion
- Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
- From White Elephant to Favorite Things parties, here are all the rules you need to know every kind of gift exchange
